Sophoricoside ameliorates cerebral ischemia-reperfusion injury dependent on activating AMPK.
Eur J Pharmacol
; 971: 176439, 2024 May 15.
Article
en En
| MEDLINE
| ID: mdl-38401605
ABSTRACT
AIMS:
Ischemic stroke accounts for 87% of all strokes, and its death and disability bring a huge burden to society. Brain injury caused by ischemia-reperfusion (I/R) is also a major difficulty in clinical treatment and prognosis. Sophoricoside (SOP) is an isoflavone glycoside isolated from the seed of medical herb Sophora japonica L. Previously, SOP was found to be effective in anti-inflammation and glucose-lipid metabolism-related diseases. In order to investigate whether SOP has a regulatory effect on cerebral I/R injury, we conducted this study.METHODS:
Here, by application of SOP into MCAO (transient middle cerebral artery occlusion)-induced mice and OGD/R (oxygen glucose deprivation/reperfusion)-induced primary neurons, the regulation effects of SOP was analyzed by detecting neurological score of post-stroke mice, phenotypes of brains and brain sections, cell viabilities, and apoptosis- and inflammation-regulation. RNA sequencing and molecular biology experiments were performed to explore the mechanism of SOP regulating cerebral I/R injury.RESULTS:
SOP administration decreased the infarct size, neurological deficit score, neuronal cell injury, inflammation and apoptosis. Mechanistically, SOP exerted its protective effect by activating the AMP-activated protein kinase (AMPK) signaling pathway.CONCLUSION:
SOP inhibits cerebral I/R injury by promoting the phosphorylation of AMPK.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Benzopiranos
/
Daño por Reperfusión
/
Isquemia Encefálica
/
Accidente Cerebrovascular
Límite:
Animals
Idioma:
En
Revista:
Eur J Pharmacol
Año:
2024
Tipo del documento:
Article
País de afiliación:
China